Centessa Pharmaceuticals (CNTA) Stock: Buy, Sell, or Hold?
CNTA - Centessa Pharmaceuticals plc American Depositary Shares
$40.50
0.32 (0.80%)
â˛
5d:
+1.86%
30d:
+1.73%
90d:
+56.13%
WAIT
LOW Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When CNTA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CNTA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CNTA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CNTA is currently trading at $40.50, which is considered fair based on recent price action.
Technical Outlook: Technically, CNTA is in a strong uptrend. The price is currently testing key support at $39.58. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CNTA is in a strong uptrend. The price is currently testing key support at $39.58. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
48/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
64.2%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- NEUTRAL: Near Wall St target ($44.17)
- WARNING: Composite score 48/100 in the bottom quintile â this cohort historically lags the market
Support & Resistance Levels
Support Level
$39.58
Resistance Level
$40.56
Current Trend
Strong Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-22.64
Wall Street Target
$44.17
(+9.1%)
Share & Embed Analysis
Last updated: October 02, 2026 12:49 AM ET
Data refreshes hourly during market hours. Next update: 1:49 AM
Data refreshes hourly during market hours. Next update: 1:49 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CNTA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 63 BUY |
|
RNA
Atrium Therapeutics, IncâĻ |
STRONG BUY
15 analysts |
$25 | 62 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 55 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$37 | 57 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
10 analysts |
$70 | 70 BUY |
